http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
-
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
-
Corbus Pharma (CRBP) Granted FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
-
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
-
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
-
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
-
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
-
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
-
Corbus Pharma (CRBP) Appoints John Jenkins to Board of Directors
-
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
-
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
-
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
-
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
-
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
-
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
-
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
-
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
-
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
-
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
-
Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
-
Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
-
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
-
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
-
Corbus Pharma (CRBP) Reports Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
-
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
-
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
-
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
-
Corbus Pharma (CRBP) Secures $25M Development Award from Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
-
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
-
Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
-
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
-
Corbus Pharma (CRBP) Begins Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
-
Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
-
Corbus Pharma (CRBP) Commences RESOLVE-1 Phase 3 Study in Systemic Sclerosis
-
Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
-
Corbus Pharma (CRBP) Granted Patent Covering Use of Anabasum for Treatment of Rare Fibrotic Diseases
-
Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
-
Corbus Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
-
Corbus Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
-
Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements
-
Corbus Pharma (CRBP) Announces Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study
-
Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study
-
Corbus Pharma (CRBP) Receives Patent Covering Use of Anabasum for Treatment of Inflammatory Diseases
-
Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases
-
Corbus Pharma (CRBP) Announces Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
-
Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
-
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors
